Dr. Tsimikas is Professor of Medicine and the Director of Vascular Medicine at the University of California San Diego School of Medicine. His education and training included obtaining his MD degree from the University of Massachusetts Medical School, Internal Medicine training at the University of Massachusetts Medical Center, and separate fellowships in Cardiovascular Medicine, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego (UCSD) Medical Center. Dr. Tsimikas is the Founding Director of the Vascular Medicine Program withing the Cardiovascular Medicine Division. In 2014, he established the concpet of a dedicated “Lp(a) Clinic” at UCSD. Dr. Tsimikas’ research interests are translational in scope and focus on two major areas: 1-“biotheranostics”- biomarkers, molecular imaging and therapeutics targeted to oxidation-specific epitopes, and 2- Lp(a) pathophysiology and therapeutics. He has published in all of the major medical journals, including NEJM, Lancet, Nature, Cell and has over 300 original manuscripts, review articles and book chapters. He currently has a dual appointment at University of California San Diego Medical School and as Senior Vice President of Global Cardiovascular Development at Ionis Pharmaceuticals, Carlsbad, CA. He is co-inventor of 13 issued patents, and co-founder of Oxitope, Inc, Kleanthi Diagnostics and Covicept Therapeutics.


Lp(a): The next frontier90th EAS Congress 2022Plenary 2: Lipoproteins revisited: What has changed ?The lipoprotein(a) story - from risk factor to causality to clinical trials88th EAS Congress 2020Silencing genes, new targets86th EAS Congress 2018Are we ready to test the Lp(a) Hypothesis?86th EAS Congress 2018Hypertriglyceridaemia - ApoC-III and ANGPTL385th EAS Congress 2017